Processa Pharmaceuticals, Inc.
PCSA
$0.218
$0.0115.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.82% | 6.91% | -15.65% | -31.31% | -47.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.07% | 18.97% | 5.19% | -20.30% | -43.63% |
| Operating Income | -23.07% | -18.97% | -5.19% | 20.30% | 43.63% |
| Income Before Tax | -26.00% | -21.70% | -6.55% | 46.95% | 60.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.00% | -21.70% | -6.55% | 46.95% | 60.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.00% | -21.70% | -6.55% | 46.95% | 60.17% |
| EBIT | -23.07% | -18.97% | -5.19% | 20.30% | 43.63% |
| EBITDA | -23.06% | -21.32% | -8.93% | 16.98% | 41.14% |
| EPS Basic | 55.99% | 50.48% | 55.00% | 78.73% | 81.32% |
| Normalized Basic EPS | 55.99% | 50.48% | 55.00% | 65.30% | 73.02% |
| EPS Diluted | 55.99% | 50.48% | 55.00% | 78.73% | 81.32% |
| Normalized Diluted EPS | 55.99% | 50.48% | 55.00% | 65.30% | 73.02% |
| Average Basic Shares Outstanding | 288.41% | 193.61% | 133.33% | 117.53% | 99.30% |
| Average Diluted Shares Outstanding | 288.41% | 193.61% | 133.33% | 117.53% | 99.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |